Epithelial ovarian cancer has a major heritable component, but the known susceptibility genes explain less than half the excess familial risk 1 . We performed a genome-wide association study (GWAS) to identify common ovarian cancer susceptibility alleles. We evaluated 507,094 SNPs genotyped in 1,817 cases and 2,353 controls from the UK and B2 million imputed SNPs. We genotyped the 22,790 top ranked SNPs in 4,274 cases and 4,809 controls of European ancestry from Europe, USA and Australia. We identified 12 SNPs at 9p22 associated with disease risk (P o 10 À8 ). The most significant SNP (rs3814113; P ¼ 2.5 Â 10 À17 ) was genotyped in a further 2,670 ovarian cancer cases and 4,668 controls, confirming its association (combined data odds ratio (OR) ¼ 0.82, 95% confidence interval (CI) 0.79-0.86, P trend ¼ 5.1 Â 10 À19 ). The association differs by histological subtype, being strongest for serous ovarian cancers (OR 0.77, 95% CI 0.73-0.81, P trend ¼ 4.1 Â 10 À21 ).
Women with a first-degree relative diagnosed with epithelial ovarian cancer have a threefold increased risk of developing the disease 2 . Environmental and genetic factors contribute to this increased risk, but studies of twins suggest that genetic factors are more important. BRCA1 and BRCA2 mutations confer high risk of ovarian cancer and are responsible for most families with three or more ovarian cancer cases. They account for less than half the excess familial risk 3, 4 , and it is likely that the residual risk is due to a combination of common and/or rare alleles that confer moderate-to low-penetrance susceptibility 5 .
Many recent studies have reported the identification of common alleles that confer low-penetrance susceptibility to common cancers including breast, prostate and colorectal cancers and melanoma [6] [7] [8] [9] [10] [11] [12] . These studies used a genome-wide association study (GWAS) design in which the genotype frequencies of hundreds of thousands of SNPs distributed throughout the genome are compared between large numbers of cases and unaffected controls. In the current study, we conducted a three-stage GWAS to identify alleles associated with variation in the risks of invasive epithelial ovarian cancer ( Table 1) . In the first stage, we used the Illumina Infinium 610K array to genotype 620,901 SNPs across the genome in 1,890 ovarian cancer cases recruited throughout the UK (see Supplementary Table 1 for details). We enriched for likely genetic heritability by including 47 cases from families with two or more ovarian cancer cases that were negative for BRCA1 or BRCA2 mutations 4 . After excluding 73 cases that failed to meet genotyping quality control criteria, the genotype frequencies for 1,817 cases were compared with the genotypes of 2,353 UK controls that had been analyzed using the similar 550k array on the same genotyping platform as part of a GWAS for other phenotypes (Supplementary Table 1 ). All the subjects analyzed in stage 1 were of European ancestry. After excluding 80,327 SNPs that were not genotyped on controls or failed to genotype on cases, a total of 507,094 SNPs with a minor allele frequency (MAF) of at least 1% in controls passed genotype quality control criteria. We also evaluated B2 million more SNPs with genotypes imputed using the phase 2 HapMap data for the samples of white European ancestry (CEU).
Supplementary Figure 1a shows the quantile-quantile (Q-Q) plot of the distribution of test statistics for comparison of genotype frequencies in cases versus controls (1 degree of freedom (d.f) Cochran-Armitage trend test) for SNPs genotyped in stage 1. There was little evidence of any general inflation of the test statistics (estimated inflation factor l 1000 ¼ 1.026 based on the bottom 90% of the distribution 13 ). This is consistent with the population structure in the UK and that for other GWAS that have used UK populations 9, 14 .
In a second stage, 23,590 SNPs were genotyped in ten studies comprising 4,964 cases of invasive epithelial ovarian cancer and 5,379 controls (Table 1 ) using the Illumina iSelect platform. We selected 22,790 SNPs based on the lowest P trend in tests for association with ovarian cancer risk from the B2.5 million genotyped and imputed SNPs and 800 SNPs that reported on ancestry. Data for 273 subjects were excluded because they did not meet quality control criteria; thus, genotyping data were available on 4,833 cases and 5,237 controls. In stage 2, 559 cases and 428 controls were of non-European ancestry and excluded from the main analyses. Supplementary Figure 1b shows the Q-Q plot for SNPs genotyped in stage 2. Again, there was little evidence of any general inflation of the test statistics for stage 2 (l 1000 ¼ 1.005). In the combined analysis of stage 1 and stage 2 data, we identified 12 SNPs associated with ovarian cancer risk with P o 10 À8 (Supplementary Table 2 ). All 12 SNPs were located in the same region on chromosome 9 (9p22.2). The strongest association was for rs3814113, which was the only SNP retained in a multivariate logistic regression model. We genotyped rs3814113 in 3,089 more cases of invasive epithelial ovarian cancer and 5,340 controls from ten studies that are part of the Ovarian Cancer Association Consortium (OCAC) (Supplementary Table 1) . Excluded from the analysis were 419 cases and 672 controls of self-reported non-European ancestry. These additional data reinforced the evidence of association for rs3814113; P trend ¼ 5.1 Â 10 À19 based on data from all three stages ( Table 2) .
rs3814113 was associated with a decrease in the risk of ovarian cancer in carriers of the minor allele (minor allele OR ¼ 0.82, 95% CI 0.79-0.86). The effect size was similar in stages 1 and 2, but slightly smaller in stage 3. There was no heterogeneity in the OR estimates among studies for any stages ( Table 2 and Fig. 1a) . Based on an OR of 0.82 and MAF of 0.32, this locus explains approximately 0.7% of the polygenic component of ovarian cancer risk. This estimate is also based on the assumptions that the known high-penetrance genes explain 40% of the excess familial risk and the unexplained component is polygenic. There was no significant difference between the risk of ovarian cancer in subjects of European and non-European ancestry (P ¼ 0.83). However, the per-minor allele risk was slightly attenuated and not significant in the subjects of non-European ancestry (OR ¼ 0.89, 95% CI 0.78-1.01, P ¼ 0.077) (Supplementary Table 3) .
We also evaluated the association for rs3814113 with ovarian cancer risk after stratifying cases by histological subtype. The strength of association increased when serous cases (n ¼ 4,847), the most common histological subtype, were considered alone (OR ¼ 0.77, 95% CI 0.73-0.81, P trend ¼ 4.1 Â 10 À21 ) (Supplementary Table 4 and Fig. 1b) . When the analysis was restricted to serous cases the effects were similar between European and non-European subject (non-European OR ¼ 0.79, 95% CI 0.66-0.94, P ¼ 0.007). a The numbers of subjects who were excluded from analysis because of failing genotyping quality control criteria are presented in parentheses. We detected only marginal evidence of association for rs3814113 in 1,320 cases diagnosed with endometrioid ovarian cancer (OR ¼ 0.86, 95% CI 0.79-0.94, P trend ¼ 0.001) and no association for patients with mucinous (n ¼ 626) or clear cell (n ¼ 628) ovarian cancer (Supplementary Table 4 ). However, the small numbers of mucinous or clear cell cases limited the power to detect modest effects. Compared to the non-serous subtypes, the ovarian cancer risk in serous cases was significantly lower (P ¼ 7.8 Â 10 À5 ). There was also some suggestion of a larger effect in older women (P trend ¼ 0.006 for ovarian cancer overall and P trend ¼ 0.044 for serous ovarian cancer) (Supplementary Table 5 ). There was no significant difference in genotype frequency for cases reporting a family history of ovarian cancer compared with cases with negative family history of ovarian cancer (P ¼ 0.59).
All 12 SNPs in the region that were identified after stage 2 were in the same linkage disequilibrium block and were associated with a decreased risk of ovarian cancer, perhaps suggesting that susceptibility is driven by a single, correlated variant within the region (Fig. 2) , although it is possible that there are multiple independent SNPs all correlated with the best markers. rs3814113 may be the causal SNP on 9p22.2 or it may be a marker in linkage disequilibrium with the true functional variant or haplotype. Neither rs3814113 nor the highly correlated SNP rs4445329 (r 2 BNC2, B128 kb upstream of LOC648570 and B220 kb downstream of CNTLN. Eight of the associated SNPs in the region are located within intron 2 of BNC2 (Fig. 2) . BNC2 encodes a DNA-binding zinc-finger protein that is highly conserved across vertebrates, and may be important regulatory protein for DNA transcription 15 . The gene shows extensive transcriptional variability, with six promoters and the potential to generate up to 90,000 mRNA isoforms encoding more than 2,000 different proteins 16 . The Genevar project provides data on gene expression of BNC2 in lymphocyte-derived cell lines from the CEU population based on nine probes in the region 17 . There was no association between any of these probes and genotype at the top 12 SNPs. Also, none of the top 12 SNPs seem to be near predictable or known enhancer binding sites or splice sites using PupaSNP (see URLs). BNC2 is highly expressed in reproductive tissues (ovary and testis) and may play a role in the differentiation of spermatozoa and oocytes 18 . There is little evidence of a role for BNC2 in cancer development, although there is a report of B7-9-fold upregulated expression in basal cell carcinoma compared to normal basal cells 19 .
Resequencing of the 9p22.2 region and further genotyping in ovarian cancer cases and controls will be needed to clarify the likely causal variant(s). We found no other susceptibility loci reaching genome-wide significance (P o 10 À8 ) in this study. Positive associations have previously been reported in candidate gene studies, but none of these reached genome-wide significance. Supplementary Table 6 shows some of the more notable published associations [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] together with our results for the same SNPs from this study. In general the reported associations and our results are consistent, but none of the associations in this study ranked highly enough for the SNP to be included in the stage 2 genotyping. The power to have identified rs3814113 depends on the true relative risk. Assuming a relative risk per minor allele of 0.82 (combined data estimate), power was 490% at genome-wide significance, suggesting that common alleles of larger effect are unlikely to have been missed. However, if the true per-allele relative risk is 0.88 (stage 3 estimate), then power was only 20%, suggesting that susceptibility alleles with more modest effects remain to be identified. Furthermore, power to detect less common alleles will be limited unless the effect on risk is greater. For example, we have 90% power at genome-wide significance to detect a risk allele with 5% frequency that confers a relative risk of 1.44. This would be consistent with findings for other common cancer types (for example, breast cancer and prostate cancers) 29 . In addition, disease heterogeneity may have limited our power to identify additional susceptibility alleles. In the primary analysis, we considered ovarian cancer as a single disease phenotype, but the effects of association for rs3814113 varied when cases were stratified by histological subtype. Different subtypes of ovarian cancer have different biological properties, and this finding supports previous studies that suggest susceptibility due to germline genetic variation may be subtype specific. For example, serous and endometrioid cancer are relatively more common in BRCA1 and BRCA2 mutation carriers, whereas mutations in the DNA mismatch repair genes are more frequently associated with mucinous ovarian cancers [30] [31] [32] . More ovarian cancer susceptibility loci may exist that are associated with specific histological or molecular subtypes 33 . However, the power to identify alleles for the rarer subtypes (endometrioid, mucinous and clear cell ovarian cancers) was limited by the numbers of cases in the study. It is likely that pooling of data from multiple ovarian cancer GWAS will enable identification of additional susceptibility alleles for invasive ovarian cancer and for specific subtypes.
The identification of common ovarian cancer susceptibility variants may have future clinical implications in identifying patients at greatest risk of the disease. Survival rates in patients diagnosed with ovarian cancer are poor-approximately 70% of patients are diagnosed with late-stage disease, and less than 40% of these people survive more than 5 years after their diagnosis. The efficacy of using multimodal approaches to early detection of the disease is limited, but it may be improved by using genetic risk profiling to identify individuals who would benefit most from earlier disease detection. The benefits of a similar approach have recently been modeled in breast cancer 5 . Identifying genetic variants that cause ovarian cancer may also improve our understanding of the underlying biology of ovarian cancer, potentially leading to the development of more effective, individualized therapies. For example, functional characterization of the highly penetrant susceptibility genes BRCA1 and BRCA2 has since led to the development of a potential therapy for patients deficient in BRCA1 or BRCA2 function based on inhibition of the poly(ADP-ribose) polymerase (PARP) DNA repair pathway 34, 35 . The 9p22.2 region is the first common susceptibility locus for ovarian cancer to be established. Understanding the mechanisms by which this susceptibility is mediated should improve our understanding of the biology of ovarian cancer and may lead to new approaches to treating or preventing the disease.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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ONLINE METHODS
Study design. The ovarian cancer case-control studies that participated in stages 1, 2 and 3 are summarized in Supplementary Table 1 . Stage 1 comprised invasive epithelial ovarian cancer cases from UK and genotype data of UK controls from GWAS of other phenotypes. Stage 2 comprised ten studies from the OCAC. Stage 3 comprised ten additional studies from the OCAC. For all studies we have data on disease status, age at diagnosis and date of blood draw, self-reported ethnic group and histological subtype. All but five studies provided information of reported first-degree family history of ovarian cancer.
Genotyping. Genotyping for stage 1 cases was conducted using the Illumina Infinium 610K array at Illumina Corporation. Existing data from two sets of controls, genotyped on the Infinium 550k array, were used in stage 1 analyses: the Welcome Trust Case-Control Consortium 1958 birth cohort 14 and a national colorectal control study 36 using Illumina platform Hap550 array. All cases were from the UK and confirmed as invasive epithelial ovarian cancer. Quality control criteria were applied separately to the cases and each control sets because they were genotyped separately. SNPs were excluded if (i) they deviated from Hardy-Weinberg equilibrium (HWE) at P o 10 À4 or (ii) had a MAF o 1%, or (iii) MAF was between 1% and 5% and call rate o 99% or (iv) MAF 4 5% and call rate o 95%. We also rejected SNPs if a test for trend by genotype between the two control sets was significant at P o 10 À4 . This led to 33,479 SNPs being excluded and 507,094 SNPs passing QC. Genotyping the ten studies in stage 2 was conducted using an Illumina iSelect array at Illumina Corporation. We excluded SNPs (n ¼ 1,635) for the stage 2 data if the sum of the test statistics for deviation from HWE for the ten studies was significant at P o 10 À5 or if the SNPs had a call rate of o95% or if the MAF o 0.5%. A total of 21,955 SNPs were available for data analysis in stage 2.
We used only samples with called genotypes on at least 80% of SNPs. Seventy-three samples were excluded from Stage 1 and 273 from Stage 2. Nineteen samples were included as duplicates in stage 1 and genotype concordance rate for these pairs was 99.99%. One hundred and twenty-two samples were included as duplicates in stage 2 and duplicate concordance rate was 99.99%. Six studies in stage 3 were genotyped for rs3814113 by Taqman using ABI Prism 7900HT sequence detection system at each laboratory. For three studies (TOR, NCO, MAY) genotype data were available from an independent, ongoing GWAS study that is also used the Illumina Infinium 610K platform. Genotyping and QC was performed at Mayo Clinic genotyping shared resources. For Taqman genotyping quality control, we compared genotype call rates and concordance by study and overall. We used the following criteria as a measure of acceptable genotyping: (i) 4 3% sample duplicates included; (ii) concordance rate for the duplicates Z 98%; (iii) overall call rate (by study) 4 95%; (iv) call rates 4 90% for each individual 384-well plate and (v) no deviation from HWE in controls (P 4 ¼ 0.05). Genotyping consistency across laboratories using Taqman was also evaluated by genotyping a common panel of CEPH (Centre d'Etude du Polymorphisme Humain)-Utah trios including 90 individual DNA samples, 5 duplicate samples and 1 negative control. The concordance of genotyping results between the centers was required to be greater than 98% in order for the genotype data to be included. The genotyping results from all studies in the stage 3 met the above criteria and were included in the final analysis.
Population stratification. For the stage 1 samples, we used the program LAMP 37 to assign intercontinental ancestry based on the HapMap (release no. 22) genotype frequency data for European, African and Asian populations. Samples with less than 90% European ancestry were excluded from the analysis (n ¼ 73). For the stage 2 data, 800 SNPs that are known to be predictive of ancestry ('Ancestry Informative Markers' (AIMs)) were genotyped. We again used LAMP and the HapMap data (release no. 23) on European (CEU), African American (ASW), East Asian (JPT-CHB-CHD), Mexican (MEX) and Indian (GIH) populations to estimate ancestry. Subjects with less than 90% European ancestry were excluded from the main analyses (n ¼ 987). We then used the AIMs to calculate principal components for the subjects of European ancestry. The first principal component explained 0.42% of the variability and was included as a covariate in subsequent association analyses. Subsequent principal components were not included as they and explained less variability and there was little difference in their eigenvalues.
Imputation. We imputed missing genotype data for all the common variants in the HapMap data for two reasons. First the stage 1 cases and controls were genotyped using slightly different SNP sets and different SNPs may have failed QA in different sample sets. Second, imputing SNPs that have not been genotyped increases genome coverage and may improve power. We used an in-house method that combines the features of fastPHASE 38 and IMPUTE 39 to impute the ungenotyped or missing SNPs, using the phase 2 HapMap data (CEU) which contains phased haplotypes for 60 individuals on 2.5 million SNPs. For each imputed genotype the expected number of minor alleles carried was estimated (weights). Genotyped SNPs were assigned weights of 0, 1 or 2 (actual number of minor alleles carried). We estimated the accuracy of imputation by calculating the estimated r 2 between the imputed and actual SNP 40 . SNPs with r 2 o 0.64 were excluded (n ¼ 152,401) leaving a total of 2,563,972 SNPs for stage 1 analysis.
Statistical tests of association. We used logistic regression to test for association between genotype and case-control status using the imputed weights and the ethnicity estimates as covariates. SNPs were selected for replication in stage 2 based on the weighted ranked test statistics from the stage 1 analysis. The weights were based on whether the SNP was genotyped or imputed (I genotype ¼ 1 if genotyped, 0 otherwise), the accuracy of imputation (r 2 ), the association statistic (T) and the design score (s) using the somewhat arbitrary formula (1 + 0.1I genotype ) Â T Â r 2 + 2s. SNPs that were correlated with a higher ranked SNP with r 2 4 0.8 were excluded except for those correlated with the 1,000 highest ranked SNPs. Using this method we took forward 22,790 SNPs as candidates for association of which 5,380 were purely imputed (non-genotyped). For the stage 2 analysis, we tested for association by performing logistic regression using the imputed values from stage 1, combined with the genotyping results for stage 2. We corrected for the first principal component and the ethnicity estimates in the second stage analysis (all subjects in the first stage were selected to be European) and stratified by study using a Wald test. We corrected for ethnicity in stage 3 using self-reported ethnicity and stratified by study. A subgroup analysis was used to compare genotype-specific risks by disease subgroup with controls. The effect of age group, family history and population of origin (European and non-European) was assessed similarly. Modification by these subgroups was tested by fitting a SNP by subgroup interaction term in a logistic regression model.
